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Abstract
Context
Moderate-to-vigorous physical activity (MVPA) and sedentary time (ST) are important for
child and adolescent health.
Objective
To examine habitual levels of accelerometer measured MVPA and ST in children and ado-
lescents with chronic disease, and how these levels compare with healthy peers.
Methods
Data sources: An extensive search was carried out in Medline, Cochrane library, EMBASE,
SPORTDiscus and CINAHL from 2000–2017.
Study selection: Studies with accelerometer-measured MVPA and/or ST (at least 3 days
and 6 hours/day to provide estimates of habitual levels) in children 0–19 years of age with
chronic diseases but without co-morbidities that would present major impediments to physi-
cal activity. In all cases patients were studied while well and clinically stable.
Results
Out of 1592 records, 25 studies were eligible, in four chronic disease categories: cardiovas-
cular disease (7 studies), respiratory disease (7 studies), diabetes (8 studies), and malig-
nancy (3 studies). Patient MVPA was generally below the recommended 60 min/day and ST
generally high regardless of the disease condition. Comparison with healthy controls sug-
gested no marked differences in MVPA between controls and patients with cardiovascular
disease (1 study, n = 42) and type 1 diabetes (5 studies, n = 400; SMD -0.70, 95% CI -1.89
to 0.48, p = 0.25). In patients with respiratory disease, MVPA was lower in patients than
controls (4 studies, n = 470; SMD -0.39, 95% CI -0.80, 0.02, p = 0.06). Meta-analysis
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indicated significantly lower MVPA in patients with malignancies than in the controls (2 stud-
ies, n = 90; SMD -2.2, 95% CI -4.08 to -0.26, p = 0.03). Time spent sedentary was signifi-
cantly higher in patients in 4/10 studies compared with healthy control groups, significantly
lower in 1 study, while 5 studies showed no significant group difference.
Conclusions
MVPA in children/adolescents with chronic disease appear to be well below guideline rec-
ommendations, although comparable with activity levels of their healthy peers except for
children with malignancies. Tailored and disease appropriate intervention strategies may be
needed to increase MVPA and reduce ST in children and adolescents with chronic disease.
Introduction
Children and adolescents with low levels of physical activity (PA) are at increased risk of
becoming inactive adults, and of diseases which result from inadequate activity [1, 2]. In addi-
tion to low PA, there is increasing concern that high levels of sedentary time (ST) may also be
common, and both low PA and high ST are important risk factors for chronic disease [3, 4].
Multiple national and international bodies have recommended a minimum of 60 minutes of
moderate-to-vigorous intensity physical activity (MVPA) every day for school-age children
and adolescents [5, 6]. These recommendations for the general population are usually also
considered to be applicable to children and adolescents with chronic disease [7–9], with an
understanding that usual levels of MVPA might be lower in such sub-groups, and achievement
of the MVPA recommendation would be a slower and more gradual process than in the
healthy population [7, 10–12].
Objective techniques such as accelerometry currently represent the most accurate methods
for measuring the amount and intensity of PA and amount of ST [13, 14]. While there have
been many studies on the levels and adequacy of MVPA and ST in healthy children and ado-
lescents [15–18], there are surprisingly few such studies in children and adolescents with
chronic disease. In fact, numerous previous studies and national PA surveillance programs
have actually excluded children and adolescents with chronic disease.
The primary aim of the present study was therefore to examine whether children and ado-
lescents with chronic disease met the current MVPA recommendation [1, 6, 19]. Secondary
aims were to examine the amount of accelerometer-measured ST in children and adolescents
with chronic diseases, and to determine whether accelerometer measured MVPA and ST in
children and adolescents with chronic disease were different from those in healthy control or
comparison groups. This systematic review provides evidence on whether levels of MVPA are
adequate and ST excessive in children and adolescents with chronic disease.
Methods
Review governance and registration
A systematic review of the literature was performed in accordance with the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [20] as shown
in S1 File. The review protocol was registered on PROSPERO (registration number
CRD42015016783), the international prospective register for systematic reviews (http://www.
crd.york.ac.uk/NIHR_PROSPERO) see S2 File.
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Study eligibility
Inclusion criteria: To be eligible for inclusion in the review, papers had to meet all of the
following criteria as per PICOS principles: Population (children and adolescents aged from
0–19 years); Intervention or exposure: chronic childhood disease (chronic disease defined as
any physical health problem that lasts three months or more). The chronic diseases included
were decided on following a scoping review and were cardiovascular disease, respiratory dis-
ease, diabetes type 1 or type 2, and malignancies); Comparison (where applicable): healthy
children matched for relevant criteria (in particular age, gender); Outcome (accelerometer
measured MVPA and/or ST of at least 3 days and 6 hours/day). All study designs were consid-
ered eligible (cross-sectional, longitudinal, case-control studies and intervention studies if pre-
intervention data could be extracted). We looked for original research studies, published in
English, in peer-reviewed journals; a detailed description of the study eligibility criteria is
given in S1 Table.
Exclusion criteria: Studies that included participants with co-morbid acute or chronic
medical diseases or conditions that may have impacted their physical activity were excluded.
The present study aimed to examine the subtle impact of chronic disease on MVPA and ST,
not the more obvious impacts from co-morbidities that preclude physical activity (e.g. arising
from injury or acute illness requiring bed rest, and chronic physical limitations from e.g. cere-
bral palsy). Because of the on going debate about whether obesity is a disease, studies in chil-
dren with obesity were also excluded and are the subject of a separate report.
Since the aim of the review was to examine habitual levels of MVPA and ST, studies that
measured these variables for less than 6 hours per day or over two days or less were excluded.
Recommendations currently exist for habitual (overall) MVPA rather than MVPA during spe-
cific domains (e.g. the after school period) and so studies that focused only on specific periods
of the day (e.g. school activity only, or outdoor activity only, or weekend or weekday activity
only, or after-school only) were also excluded.
Search strategy. The literature search was conducted using the five most relevant elec-
tronic databases: MEDLINE OVID; Cochrane library; EMBASE; SPORTSDiscus and
CINAHL. We searched from the year 2000 (to increase generalisability, since levels of MVPA
and/or ST might be different now than in the past, and because accelerometry became more
widely used in research from the early 2000’s) up to March 2017. The literature search strategy
used in MEDLINE is given in Table 1, and was adapted as required for the other four data-
bases. Full literature search details are available from the corresponding author on request.
The electronic search was complemented by reference tracking (forward and backward) of the
eligible studies.
Study selection. Titles, abstracts, and full-text articles were screened in duplicate for eligi-
bility and disagreements were resolved through discussions with other reviewers when
required. Reference lists of eligible studies were examined for potentially eligible studies. Rea-
sons for exclusion are summarised in the study flow diagram and available in details from the
corresponding author on request.
Data extraction and data synthesis. This review used a standard form for extracting rele-
vant information from the eligible studies. The systematic review identified that the eligible
studies fell logically into four categories: cardiovascular disease; respiratory disease; diabetes;
malignancy. A fifth category (obesity) was identified but this is reported separately as noted
above. Obesity was not included here because of the on-going debate about whether obesity is
a disease or not. International recommendations for school-age children and adolescents spec-
ify at least 60 minutes of MVPA every day [5, 6], but in the eligible studies the achievement of
MVPA recommendations was never operationalised in this way. In most studies, only the
Activity in children with chronic disease: A systematic review and meta-analysis
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Table 1. Search strategy used for MEDLINE database.
1. exp Child/
2. exp Adolescent/
3. (child* or adolesc* or teen* or youth or girl* or boy*).tw.
4. (young adj1 (person or people)).tw.
5. 1 or 2 or 3 or 4
6. exp Exercise/
7. exp Motor Activity/
8. exp Sports/
9. exercis*.tw.
10. physical* activ*.tw.
11. (active adj2 (living or lifestyle)).tw.
12. sedentary behavi?r.tw.
13. exp Sedentary Lifestyle/
14. ((sedentary or sitting or screen or TV or television or computer or PC or video games) adj2 time).tw.
15. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. exp Obesity/ or exp Overweight/
17. (overweight or obes*).tw.
18. exp Accelerometry/
19. exp Actigraphy/
20. acceleromet*.tw.
21. actigraph.tw.
22. activity monitor*.tw
23. (objective adj1 (measure* or monitor* or assess*)).tw.
24. 18 or 19 or 20 or 21 or 22 or 23
25. exp cardiovascular abnormalities/ or exp heart diseases/
26. exp Cardiovascular Abnormalities/
27. exp Heart Diseases/
28. "congenital heart disease".tw.
29. "Atrial Septal Defect".tw.
30. "Complete Atrioventricular Canal Defect ".tw.
31. "Ventricular Septal Defect".tw.
32. (Tetralogy adj2 Fallot).tw.
33. exp Asthma/
34. asthma.tw.
35. exp Respiratory Tract Diseases/
36. exp Respiratory Hypersensitivity/
37. exp Cystic Fibrosis/
38. (respiratory adj2 allerg*).tw.
39. "cystic fibrosis".tw.
40. wheez*.tw.
41. exp Bronchopulmonary Dysplasia/
42. lung diseases/ or exp alpha 1-antitrypsin deficiency/ or exp "cystic adenomatoid malformation of lung,
congenital"/ or exp hepatopulmonary syndrome/ or exp hypertension, pulmonary/ or exp lung diseases,
fungal/ or exp lung diseases, interstitial/ or exp lung diseases, obstructive/ or exp lung diseases, parasitic/
or exp lung injury/ or exp lung neoplasms/ or exp lung, hyperlucent/
43. "chronic lung disease".tw.
44. "chronic respiratory disease".tw.
45. exp diabetes mellitus, type 1/ or exp diabetes mellitus, type 2/
46. (diabetes adj1 mellitus).tw.
(Continued )
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mean or median daily MVPA was provided (rather than achievement of MVPA recommenda-
tions on 7/7 days), and so this was used as a proxy for achievement of guideline recommenda-
tions in the present study.
Where suitable data for patients and healthy controls were reported, mean and standard
deviation of MVPA and ST in minutes per day, and sample sizes for similar chronic disease
conditions were combined in a random effects model accounting for heterogeneity between
studies. Given the differing methods of determining MVPA levels obtained from accelerome-
ters, differences in MVPA between patients and controls were generated as weighted standard-
ised mean difference (SMD). While methodology (e.g. accelerometer model, accelerometry
cut point and/or epoch) varied substantially between studies, within study comparisons are all
based on the same methods. Separate meta-analyses were performed for MVPA and ST.
Review Manager 5.2 was used for the quantitative analysis [21]. Some eligible studies recruited
healthy control participants and measured MVPA and/or ST in the same way as in their
patient group and at the same time (referred to here as studies with controls), while other stud-
ies compared patient data with other studies (e.g. published data) and are referred to here as
studies with comparison groups; some studies simply reported patient data in relation to phys-
ical activity recommendations.
Quality assessment. Eligible articles were assessed for methodological quality using a
15-item quality assessment scale as shown in S2 Table, collapsed to 6 items for scoring, with
higher scores suggesting higher study quality. Each eligible study was assessed independently
by two authors (RE, JJR), and disagreements were resolved by discussion. The quality assess-
ment scale was modified from the methodological quality assessment scale of Tooth et al. [22].
This is a reliable and valid 30-item tool for assessing the quality of observational studies, and
was considered for use without modification initially. After careful reflection, modifications to
the original scale were made to focus quality assessment on issues of particular importance to
accelerometry measurement of PA. A modified Tooth tool has been used previously with sev-
eral recent systemic reviews of PA studies with 8–17 items, that were usually collapsed to a
smaller number of items for scoring [23–26].
Table 1. (Continued)
47. exp Leukemia/
48. Leukemia.tw.
49. exp Lymphoma/
50. Lymphoma.tw.
51. exp Neuroblastoma/
52. Neuroblastoma.tw.
53. "Wilms’ tumor".tw.
54. exp Central Nervous System Neoplasms/
55. exp Sleep Apnea Syndromes/
56. "sleep apnea".tw.
57. 16 or 17 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or
41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56
58. 5 and 15 and 24 and 57
59. exp Adult/.
60. 58 not 59
61. limit 60 to (english language and yr = "2000 -Current")
https://doi.org/10.1371/journal.pone.0179429.t001
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Results
Identification of eligible studies
The PRISMA flow diagram with numbers of included and excluded articles at each step of the
review process is provided in Fig 1. Tables 2–5 provide a brief summary of all studies included
in this systematic review. Of the 1592 identified records from the five databases, 504 were
selected for full text screening and of these, 24 met the inclusion criteria. Additionally, 1 study
was identified and deemed eligible through searching references of eligible studies, bringing
the final total to 25 eligible studies (7 in cardiovascular disease; 7 in respiratory disease; 8 in
diabetes; 3 in malignancies) and 11 of these 25 studies were suitable for inclusion in meta-anal-
ysis (4 in those with respiratory disease; 5 in those with diabetes; 2 in those with malignancies).
All eligible studies measured MVPA, and 16 out the 25 eligible studies compared levels of
MVPA between patients with chronic disease and a healthy control group (referred to here as
studies with controls), while the other 8 eligible studies compared data from patients with data
Fig 1. The PRISMA flow diagram with numbers of included and excluded articles at each step of the
review process.
https://doi.org/10.1371/journal.pone.0179429.g001
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from previously published studies of healthy children and adolescents (referred to here as stud-
ies with comparison groups); and two studies simply reported patient data in relation to rec-
ommendations; 14 of the 25 studies also provided data on ST, and 10 of these 14 studies
compared ST in those with chronic disease with a healthy control group, while another 4 eligi-
ble studies compared data from patients with data from previously published studies of healthy
children and adolescents comparison groups.
Study characteristics. Study samples: Eligible study sample sizes ranged from 14–699
with a total of 2062 participants with chronic disease and 1523 participants from healthy con-
trol groups. All studies were from high-income, developed nations. Measurement methods: A
total of 17 out of the 25 eligible studies used the ActiGraph accelerometer to measure habitual
MVPA and/or ST, though with a variety of different ActiGraph models and approaches to data
collection and reduction. Of the remaining studies: three used the Actical [28, 33, 53]; two the
RT3 “Triaxial Research Tracker” [37, 40]; one the PAM “Physical Activity Monitor” B.V. type
AM 100 [41]; one the Actiheart (which combines accelerometry and heart rate monitoring)
[49]; and one the Step Watch 3™ [52].
Table 5. Descriptive characteristics and levels of moderate-to-vigorous intensity physical activity and sedentary time in children with
malignancies.
Reference* Place and
publication
year
Sample
group
n, male%
and age
(yrs)
Control
group
n, male%
and age
(yrs)
Measurement Accelerometry
methods
MVPA Sedentary time
Aznar et al
[51]
Spain, 2006 n: 7,
(57.1%
male)
n: 7,
(57.1%
male
Actigraph MTI, worn
on waist for 7 days
during waking hours
Epoch = 60s,
Freedson cut-point
[35]
Patients mean 47 (SD
15) min/day
Patients mean 41 (SD
18) % of time
sedentary
Age: range
4–7
Age: range
4–7
Sedentary
time 100 cpm
Control group mean 72
(SD 25) min/day
Control group mean
42 (SD 11) % of time
sedentary
Significantly lower in
patient group than
control group (p = 0.04)
Sedentary time was
similar in patient and
control group
(p = 0.07)0% of patient, 57%
control group achieved
an average of 60 min/
day of MVPA
Gotte et al
[52]
Germany,
2017
n: 28, (57%
male)
N/A Step Watch 3™
Monitor, worn for 7
days during waking
hours
Epoch = 60s Patients mean 4 (SD 5)
min/day
N/A
Age: range
11–15
MVPA cut-point not
clearly reported
3% (n = 1) of patient
achieved an average of
60 min/day of MVPA
Tan et al
[53]
Malaysia, 2012 n: 38 n: 38 Actical, worn on hip for
7 days during all the
day
Epoch = 15s Patients mean 20 (SD
28) min/day
Patients mean 1295
(SD 119) min/day
Age: range
3–12
Age: range
3–12
MVPA cut off points
not reported
Control group mean 168
(SD 56) min/day
Control group mean
925 (SD 111) min/day
Sedentary
time < 100 cpm
Significantly lower in
patient group than
control group (p < 0.01)
Significantly higher in
patients than control
group (p < 0.01)
cpm: counts per minutes; MVPA: moderate-to-vigorous physical activity; n: Number; S: Second; Data are expressed as mean (SD) unless otherwise;
Freedson MVPA cutpoint [35] calculated using the following equation: METS = 2.757 + (0.0015 x counts/min)–(0.08957 x age (yr))–(0.000038 x counts/min
x age (yr))
*2 studies [51, 53] recruited healthy control participants and measured MVPA and ST in the same way as in their patient participants and at the same time
(referred to here as studies with control group), 1 study [52] reported patient data in relation to recommendations.
https://doi.org/10.1371/journal.pone.0179429.t005
Activity in children with chronic disease: A systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0179429 June 22, 2017 11 / 20
MVPA in children and adolescents with chronic disease
The mean reported daily MVPA accumulated by children and adolescents with chronic dis-
ease across the 25 eligible studies ranged between 4 (SD 4) minutes/day [52] to 265 (SD 83)
minutes/day [39].
Children and adolescents with cardiovascular disease: Seven of the 25 eligible studies
(n = 442) examined MVPA in children and adolescents previously diagnosed with a congenital
heart defect. This included children who had received different types of cardiac surgery [29,
31, 32], including complex surgery such as a fontan repair [28, 33, 34], or cardiac transplanta-
tion [27]. In all cases the patients were studied at least 6 months after surgery while well, clini-
cally stable, free of acute illness, and living in the community. As summarised in Table 2,
average daily MVPA in these studies ranged from a low of 8 (range, 4–11) min/day [27] to a
high of 49 (range, 34–60) min/day [33]. In 6/7 of eligible studies reported mean daily time
spent in MVPA in minutes and in six studies mean daily MVPA failed to reach the recom-
mended 60 minutes. Only 1 out of 7 eligible studies included data from healthy control group,
showing a higher MVPA level in the patient group compared to healthy control group
although differences were not significant [31].
Children and adolescents with chronic respiratory diseases: Seven of the 25 eligible stud-
ies (n = 1013) investigated children and adolescents with chronic respiratory diseases; five
studies in patients with asthma [38–42] and two in patients with cystic fibrosis [36, 37]. In all
cases, the children were studied while clinically stable, free of acute illness, and while living in
the community. The mean daily MVPA reported ranged from 15 (SD 3) min/day [37] to 265
(SD 8) min/day [39] as summarised in Table 3. In 2/7 eligible studies [39, 41] mean daily
reported MVPA reached or exceeded the 60 minutes recommended, though this included one
study with the exceptionally high reported levels of MVPA (30). Meta-analysis of all 4 studies
indicated lower MVPA levels in the patient group compared to the healthy control group,
approaching statistical significance. The standardised mean difference (SMD) was 0.39 (95%
CI -0.80 to 0.02, p = 0.06). The heterogeneity was substantial with an I2 statistic of 68%, as
shown in Fig 2.
Children and adolescents with diabetes: Eight of the 25 eligible studies (n = 1323)
involved children and adolescents with diabetes mellitus; 7 studies in children with type 1 dia-
betes [43, 45–50] and 1 in children with type 2 diabetes [44]. Again, in all cases the patients
were studied while clinically stable and free of acute illness or diabetes complications, and
while living in the community. As summarised in Table 4, the average daily MVPA reported
for diabetic patients ranged from a low of 8 (SD 9) min/day [44] to a high of 56 (SD 20) min/
Fig 2. Forest plot of the comparison of moderate-to-vigorous intensity physical activity between children and adolescents with chronic
respiratory diseases and healthy participants. SD: standard deviation; Std mean difference: Standardised mean difference; IV: Inverse variance;
Random: random effect model; CI: 95% Confidence interval.
https://doi.org/10.1371/journal.pone.0179429.g002
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day [48]. Of the 8 eligible studies, 7 reported mean daily MVPA in minutes and in all 7 of these
studies MVPA was< 60 minutes. Patient MVPA was compared to healthy peers in 5 studies
[43, 46–48, 50], all of which included patients with type 1 diabetes as shown in Fig 3. There
was no evidence of a statistically significant difference in MVPA in patients compared to
healthy controls (SMD -0.70, 95% CI -1.89 to 0.48, p = 0.25, n = 400). Case-control evidence
on MVPA levels appears to be lacking for patients with type 2 diabetes.
Children and adolescents with malignancies: Three studies, (n = 118) examined MVPA
in those with malignancies including one study in acute lymphoblastic leukaemia on mainte-
nance treatment [51], one in acute leukemia undergoing induction or consolidation chemo-
therapy [53] and a third in children and adolescents with different types of childhood
malignancies [52]. In all of these studies, the participants had no other co-morbid conditions
that would have been a contraindication for PA such as anemia, fever, or other difficulties with
mobility. The mean daily MVPA achieved during these studies ranged from a low of 4 (SD 4)
min/day [52] to a high of 47 (SD 15) min/day [51], as summarised in Table 5. In all three stud-
ies mean daily MVPA failed to reach the recommended 60 minutes. Two out the three studies
included data from healthy participants and in both of these studies, the level of MVPA was
significantly lower in children and adolescents with malignancies [51, 53]. Fig 4 shows the
combined result, which suggests a standardised mean difference of 2.2 (95% CI -4.08 to -0.26,
p = 0.03). Despite the apparent similarity between the studies the statistical heterogeneity was
considerable with an I2 statistic of 88%. The heterogeneity noted could be due to differences in
sample sizes, age and place of the studies, differences in the stage of treatment, or differences
in accelerometer methodology.
Fig 3. Forest plot of the comparison of daily moderate-to-vigorous intensity physical activity between children and adolescents with type 1
diabetes mellitus and healthy participants. SD: standard deviation; Std mean difference: Standardised mean difference; IV: Inverse variance; Random:
random effect model; CI: 95% Confidence interval.
https://doi.org/10.1371/journal.pone.0179429.g003
Fig 4. Forest plot of the comparison of daily moderate-to-vigorous intensity physical activity between children and adolescents with
malignancies and healthy participants. SD: standard deviation; Std mean difference: Standardised mean difference; IV: Inverse variance; Random:
random effect model; CI: 95% Confidence interval.
https://doi.org/10.1371/journal.pone.0179429.g004
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Sedentary time in children and adolescents with chronic disease
In this systematic review, 14 out of the 25 eligible studies reported on accelerometer measured
ST, with a total of 1870 participants (those with chronic disease n = 1325; healthy control
group n = 545). Of the 14 studies that measured ST, the chronic diseases studied were: cardio-
vascular disease—3 studies [29, 31, 32]; chronic respiratory diseases—4 studies [36, 39, 40, 42];
diabetes—5 studies [44–46, 48, 49]; malignancy—2 studies [51, 53].
As summarised in Tables 2–5, the mean daily time spent sedentary in these eligible studies
ranged from a low of 87 (SD 48) min/day [39] to a high of 1295 (SD 119) min/day [53]. In 10
out of the 13 eligible studies, there was a healthy control group, and in 4/10 studies ST was sig-
nificantly higher in those with chronic disease than in the healthy control groups [46, 48, 49,
53], in one study ST was significantly lower in the patient group compared to the healthy con-
trol group [36], and in 5 studies there was no significant group difference [31, 39, 40, 42, 51].
Suitable summary data for combining individual study data were only available for three stud-
ies (n = 355) in patients with chronic respiratory disease with findings indicating no statisti-
cally significant group difference in time spent sedentary (SMD -0.40, 95% CI -1.53 to 0.74,
p = 0.49, I2 = 95%).
Study quality assessment
Study quality assessment summaries are given in S3 Table: 3 studies scored 4/6; 13 scored 5/6;
9 scored 6/6 on study quality. Thus in general, studies were high methodological quality.
Discussion
This systematic review provides evidence that children and adolescents with some chronic
childhood diseases have lower than recommended levels of MVPA. In most of the eligible
studies, daily MVPA averaged less than the 60 minutes/day recommended.
When comparing MVPA level between patients and healthy control or comparison groups,
the findings indicated, within the limits of the available data, no marked differences for
patients with type 1 diabetes, CVD and chronic respiratory diseases. In patients with leukemia
compared to healthy control or comparison groups daily MVPA was significantly lower. With
the respect to sedentary time the present review found that studies fairly consistently reported
that children and adolescents with chronic disease accumulated a high amount of ST during
their waking hours.
It should be noted that recommendations for MVPA state that 60 minutes per day is a mini-
mum every day (e.g. usually operationalized as all 7 days in a week), but adherence to recom-
mendations was not operationalized in this way in any of the 25 eligible studies. We therefore
used a mean or median daily MVPA of 60 minutes as a proxy for compliance, though this is
conservative because in many cases where 60 minutes/day was reached as an average, levels of
MVPA would have fallen below 60 minutes/day on at least one of the monitored days.
Reasons for lower than recommended levels of MVPA are unclear. Children and adoles-
cents with chronic disease may experience an over-protective care environment, a lack of
supervised facilities/ opportunities for PA, and/or insufficient knowledge and self-efficacy
about the types of PA suitable for the specific disease condition [54, 55]. Such socio-environ-
mental influences could contribute to low daily MVPA and high ST. Healthcare professionals,
parents/caregivers and schools may need to be provided with adequate information and train-
ing to be able to encourage and support children with chronic disease to engage in regular and
appropriate MVPA. However, it should also be noted that reported levels of MVPA among
healthy peers were also generally low in the eligible studies, so it may be that any constraints
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on PA which apply to healthy children and adolescents also apply equally to those with chronic
disease.
We believe that the present study is the first systematic review to ask whether or not levels
of MVPA are adequate in children and adolescents with chronic childhood disease. There are
therefore no directly comparable studies, but we note that in healthy children, and particularly
in healthy adolescents, there is concern that levels of MVPA are generally much lower than
recommended. A global analysis by Hallal et al suggested that less than 20% of 13–15 year olds
meet the recommendation of 60 minutes/ day of MVPA [56]. A recent pooling of international
accelerometry data from nearly 21,000 healthy children and adolescents showed typically very
low levels of adherence to the 60 minutes/day recommendation for MVPA [57], so it is per-
haps not surprising that levels of MVPA among those with chronic disease were also found to
be generally low in the present study.
We are also unaware of any previous systematic reviews of accelerometry measured ST
among children and adolescents with chronic disease. Interpreting sedentary time data is even
more problematic than interpreting the MVPA data in the present study because there are cur-
rently no evidence-based recommendations for accelerometer-measured ST.
Our review had a number of strengths. It was the first review to investigate objective levels
of MVPA and ST in children and adolescents living with childhood chronic disease. Secondly,
there are several methodological strengths to this study: in particular, studies were identified
from an extensive search of the published literature conducted in a range of databases. The
broad definition of search terms applied across multiple databases enabled the searching and
identification across many potential studies. Restricting eligibility to accelerometry studies was
important in increasing confidence in the objective measurement of MVPA [16, 58–60].
Finally, all included studies were in general rated as being of high or very high quality.
However, there are several weaknesses worth highlighting. Firstly, as studies had to be pub-
lished in peer-reviewed journals in English, this may have excluded some relevant evidence.
Studies included in our review investigated MVPA and ST in children and adolescents with
chronic childhood disease. However, we excluded some other common medical conditions
where significant alterations in activity might have been expected because of the nature of the
condition e.g. musculo-skeletal and neurological disease, and we also excluded studies of
patients with acute illness or injury requiring or associated with confinement or bed-rest.
Future reviews should consider these other groups, and also consider the PA and ST of chil-
dren and adolescents with the many chronic diseases not included in the present review. Our
initial scoping review found that objectively measured PA data were available for only a few
chronic disease groups and so the present review focused on those.
All eligible studies were from high-income developed nations. We therefore lack data from
low-middle income countries where the prevalence of many childhood chronic disease will be
common and lack of resources may limit medical care [61]. Most of the included studies were
based on relatively small samples of children with chronic disease (n 14–699) and their power
to estimate habitual MVPA, or to distinguish between MVPA of patients and comparison
group participants, might have been limited, and their representativeness was rarely clear. Our
method for assessing the quality of eligible studies has been used in variously adapted forms in
a number of other recent accelerometry systematic reviews [23–26], and used 15 items, but the
process of collapsing these 15 items to a six-item scale might have reduced the possibility of
identifying differences in quality between studies. Eligible studies made comparisons with
healthy peers in a wide variety of ways (control groups; comparison groups; reference to rec-
ommendations). Use of control groups was considered ideal, but restricting our synthesis to
only those studies would have reduced a small evidence base to an even smaller evidence base,
so this was not done.
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Further, the eligible studies varied substantially in terms of the accelerometers used, and
even where the same accelerometer was used the methods varied in a number of potentially
important accelerometer data reduction decisions e.g. the definition of a monitoring epoch
[43, 59]; the number of hours and days of data constituting a valid data set [44, 46]; MVPA
and ST accelerometer cut-points; and criteria for the inclusion or exclusion of non-wear time
[36, 45]. These differences between studies are likely to have produced meaningful differences
in MVPA and ST estimates [13] and they make it difficult to compare across studies. For the
present review, the level of heterogeneity between eligible studies was high when combining
data in meta-analysis across studies. However, in the case of all eligible studies the methods
used for patient and control/comparison groups were identical, so comparison within-studies
remain meaningful.
An example of how the choice of accelerometer cut-point could affect conclusions reached
by individual studies is that studies using lower accelerometer cut-points to define MVPA
tended to report higher levels of habitual MVPA than those which used lower accelerometer
cut-points to define MVPA. Tsai et al [39], for example used an Actigraph accelerometer cut-
off of 700 counts per minute to define MVPA in children with asthma. This cut-off point is
well below the cut-points used more commonly and which are more evidence based (based on
calibration studies such as the Evenson et al cut-point of 2296 counts per minute [30]; or the
Puyau et al cut-point of 3200 counts per minute [62]). The very low accelerometer cut-point
used by Tsai et al almost certainly led to the very high estimate of 265 (SD 83) minutes of daily
MVPA [39], and could lead to the erroneous conclusion that levels of MVPA among children
with asthma are extremely high.
Conclusions
In summary, this systematic review found that overall (habitual) MVPA levels are well below
international recommendations in at least some groups of children and adolescents with
chronic childhood diseases. The present review suggests that management of pediatric chronic
conditions should place greater emphasis on MVPA, and patients with at least some chronic
diseases are probably not currently benefiting from the health and non-health benefits that
MVPA can bring. Time spent sedentary is often higher than in the comparison groups, and
probably too high in many patients, but this is difficult to interpret in the absence of health-
related recommendations for accelerometer measured ST in children and adolescents. This
valuable information about the MVPA and ST levels in children with chronic disease may help
to stimulate improving PA guidelines, and improving PA for these children. The need for
more extensive research in this area, including intervention studies of the impact of increased
MVPA levels on health related outcomes, is clear.
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